Search Result

Results for "

energy expenditure

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Amine N-methyltransferase (1) AMPK (1) Apoptosis (3) Calmodulin (1) Collagen (1) COX (1) Endogenous Metabolite (2) GCGR (4) GLP Receptor (4) HSP (1) JNK (1) Melanocortin Receptor (2) MetAP (2) mTOR (2) Neurokinin Receptor (1) Neuropeptide FF Receptor (1) Neuropeptide Y Receptor (2) NF-κB (3) NO Synthase (1) Olfactory Receptor (1) Opioid Receptor (2) Orexin Receptor (OX Receptor) (1) p38 MAPK (1) PGC-1α (2) Phosphodiesterase (PDE) (1) Reference Standards (2) Sirtuin (2) Src (1) TGF-β Receptor (1) TNF Receptor (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (2) Endocrinology (4) Inflammation/Immunology (4) Metabolic Disease (24) Neurological Disease (6)

By Targets:

5-HT Receptor (1)

Adrenergic Receptor (1)

Amine N-methyltransferase (1)

AMPK (1)

Apoptosis (3)

Calmodulin (1)

Collagen (1)

COX (1)

Endogenous Metabolite (2)

GCGR (4)

GLP Receptor (4)

HSP (1)

JNK (1)

Melanocortin Receptor (2)

MetAP (2)

mTOR (2)

Neurokinin Receptor (1)

Neuropeptide FF Receptor (1)

Neuropeptide Y Receptor (2)

NF-κB (3)

NO Synthase (1)

Olfactory Receptor (1)

Opioid Receptor (2)

Orexin Receptor (OX Receptor) (1)

p38 MAPK (1)

PGC-1α (2)

Phosphodiesterase (PDE) (1)

Reference Standards (2)

Sirtuin (2)

Src (1)

TGF-β Receptor (1)

TNF Receptor (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (2)

Endocrinology (4)

Inflammation/Immunology (4)

Metabolic Disease (24)

Neurological Disease (6)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P10746

EB1002	Neurokinin Receptor	Metabolic Disease
EB1002 is a highly selective, long-acting NK2R agonist. EB1002 exerts central appetite suppression, increases peripheral energy expenditure and enhances insulin sensitivity, which effectively reduces body weight, improves glucose and lipid metabolism, with favorable safety profiles. EB1002 can be used for research on diseases such as obesity and type 2 diabetes .

HY-107734

L 152804	Neuropeptide Y Receptor	Metabolic Disease Endocrinology
L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a K_i of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure .

HY-114557

NSC 90469 3,5-Diiodo-L-thyronine	JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen	Metabolic Disease Inflammation/Immunology Endocrinology
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .

HY-19870C

Setmelanotide monoacetate 5+ Cited Publications RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate	Melanocortin Receptor Calmodulin AMPK	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a K_i value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .

HY-N0046

Notoginsenoside Fe Notoginseng triterpenes; Ginsenoside Mb	Apoptosis Src	Neurological Disease Metabolic Disease Cancer
Notoginsenoside Fe (Notoginseng triterpenes; Ginsenoside Mb) is a saponin with anti-obesity and anti-neuroblastoma activities. Notoginsenoside Fe can be isolated from leaves of Panax notoginseng. Notoginsenoside Fe specifically activates paraventricular nucleus neurons in the hypothalamus, effectively reducing body weight, improving fasting blood glucose and protecting liver function by decreasing food intake, increasing resting metabolic rate and enhancing energy expenditure. Notoginsenoside Fe also inhibits the c-Src signaling pathway, blocks the proliferation and viability of human neuroblastoma cells, while improving mitochondrial dysfunction and alleviating apoptosis. Notoginsenoside Fe can be used in studies related to diet-induced obesity and neuroblastoma .

HY-14811

Beloranib ZGN-440; CKD-732 free base	MetAP NF-κB	Metabolic Disease
Beloranib (ZGN-440; CKD-732 free base) is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib can be used in research on obesity and hypothalamic obesity .

HY-117912

TRC210258	Endogenous Metabolite	Cardiovascular Disease
TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .

HY-P1349A

Orexin B, rat, mouse TFA 1 Publications Verification Rat orexin B TFA; Orexin B (mouse) TFA	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation .

HY-15691

PF-04455242	Opioid Receptor mTOR	Neurological Disease Metabolic Disease
PF-04455242 is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-04455242 blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-04455242 promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-04455242 attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-04455242 can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .

HY-14811A

Beloranib hemioxalate ZGN-440 hemioxalate; ZGN-433 hemioxalate; CDK732 hemioxalate	NF-κB MetAP	Metabolic Disease
Beloranib (ZGN-440; CKD-732 free base) hemioxalate is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib hemioxalate blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib hemioxalate significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib hemioxalate also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib hemioxalate can be used in research on obesity and hypothalamic obesity .

HY-W1006754

NNMT-IN-7	Amine N-methyltransferase	Metabolic Disease
NNMT-IN-7 (Compound 4e) is a NNMT inhibitor (IC₅₀ = 505.7 µM). NNMT-IN-7 can be used in studies of metabolic and chronic diseases .

HY-N11262

Sudachitin	Phosphodiesterase (PDE) Sirtuin PGC-1α p38 MAPK HSP TNF Receptor NO Synthase Apoptosis	Metabolic Disease Inflammation/Immunology
Sudachitin is an orally active compound that potently inhibits mouse PDE1C and human PDE4B, with IC₅₀ values of 5.0 μM and 15.0 μM, respectively. Sudachitin upregulates Sirt1 and PGC‑1α expression in skeletal muscle to regulate energy metabolism and promote mitochondrial biogenesis. Sudachitin improves lipid metabolism, glucose tolerance, insulin sensitivity, energy expenditure, and fatty acid β‑oxidation. Sudachitin activates p38MAPK signaling, induces HSP27 phosphorylation and caspase‑dependent apoptosis, and blocks EGF‑driven keratinocyte migration and proliferation. Sudachitin suppresses LPS‑induced TNF‑α, NO, and iNOS expression in macrophages and shows potent anti‑inflammatory activity. Sudachitin can be used for the research of metabolic syndrome, type 2 diabetes, and psoriasis. .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146B

Survodutide sodium BI 456906 sodium	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) sodium is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide sodium, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide sodium has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-125088

Oleoylestrone	Apoptosis	Metabolic Disease
Oleoylestrone, an adipose tissue-derived hormonal signal, is a slimming agent that decreases food intake and maintains energy expenditure .

HY-139994

XN methyl pyrazole XP	Others	Metabolic Disease Cancer
XN methyl pyrazole improves diet-induced obesity and induces energy expenditure in high-fat diet-fed mice .

HY-148349A

(2R,2R)-PF-07258669	Melanocortin Receptor	Neurological Disease Metabolic Disease
(2R,2R)-PF-07258669 is a MC4R (melanocortin 4 receptor) antagonist. (2R,2R)-PF-07258669 can be used in the study of regulating appetite and energy expenditure .

HY-106863

BRL 35135	Adrenergic Receptor	Metabolic Disease
BRL 35135 is a potent and selective β3-adrenergic receptor agonist. BRL 35135 can dose dependently increase energy expenditure, reduce weight, and only reduce fat without reducing muscle protein. BRL 35135 can significantly improve glucose tolerance and insulin sensitivity. BRL 35135 can be used to study metabolic conditions such as obesity and diabetes .

HY-186028

HOR1-C59	Olfactory Receptor	Metabolic Disease
HOR1-C59 is a highly selective Or5v1/Olfr110 agonist with an EC₅₀ of 7.12 nM. HOR1-C59 can improve glucose homeostasis, alleviate obesity and insulin resistance. HOR1-C59 is applicable for obesity-related research .

HY-P10379

palm-PrRP31	Neuropeptide FF Receptor	Others Neurological Disease
palm-PrRP31 is a potent dual receptor agonist for both GPR10 (EC₅₀=72 pM) and NPFF-R2. palm-PrRP31 activates downstream signaling pathways through binding to its receptors, GPR10 and NPFF-R2, which results in reduced appetite and increased energy expenditure. Utilizing palm-PrRP31 facilitates the study of the mechanism of action in the nervous system, thereby elucidating the complex biological processes that regulate appetite and energy expenditure .

HY-162302

NMY1009	Others	Metabolic Disease
NMY1009 is a lipophilic C8-hydrocarbon chain conjugated analog that links mitochondrial uncouplers via ether linkages. NMY1009 can be released and enter the mitochondrial matrix and intermembrane space, thereby targeting mitochondrial uncoupler to adipose tissue and increasing energy expenditure in brown and white adipose tissue .

HY-117119

VER-3323	5-HT Receptor	Metabolic Disease
VER-3323 is an oral active 5-HT_2C agonist and belongs to the class of indoline analogs. VER-3323 reduces food intake in rats by inducing swallowing dysfunction, with no significant impact on energy expenditure generated through thermogenesis or exercise. VER-3323 can be utilized in obesity research .

HY-15691A

PF-4455242 hydrochloride	Opioid Receptor mTOR	Neurological Disease Metabolic Disease
PF-4455242 hydrochloride is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-4455242 hydrochloride blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-4455242 hydrochloride promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-4455242 hydrochloride attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-4455242 hydrochloride can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .

HY-114557R

NSC 90469 (Standard) 3,5-Diiodo-L-thyronine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .

HY-107734R

L 152804 (Standard)	Reference Standards Neuropeptide Y Receptor	Metabolic Disease Endocrinology
L 152804 (Standard) is the analytical standard of L 152804 (HY-107734). This product is intended for research and analytical applications. L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a K_i of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure .

HY-181709

TPM003 TG062	GLP Receptor GCGR	Metabolic Disease Inflammation/Immunology
TPM003 (TG062) is a triple agonist of GLP-1R, GIPR and GCGR, with EC₅₀ values of 33.9, 12.5 and 92.9 pM, respectively. TPM003 suppresses appetite, regulates blood glucose, enhances insulin sensitivity, reduces gastrointestinal intolerance, promotes hepatic lipid mobilization and increases energy expenditure. TPM003 induces weight loss, improves metabolic parameters, reverses hepatic steatosis and optimizes liver function markers. TPM003 is applicable for research on obesity and non-alcoholic steatohepatitis .

Cat. No.	상품명

HY-L087

Anti-Obesity Compound Library	3,558 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

3,558 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	상품명	Target	Research Area